Evidence map›Paper›PMID 38290838›Full record

ArticleJournal of neurology, neurosurgery, and psychiatry2024

The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.

Ganesha Liyanage, Benjamin P Trewin, Joseph A Lopez, Jane Andersen, Fiona Tea, Vera Merheb, Kristy Nguyen, Fiona X Z Lee, Marzena J Fabis-Pedrini, Alicia Zou and 16 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, neurosurgery, and psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 2 countries.

Ganesha LiyanageBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Benjamin P TrewinTranslational Neuroimmunology Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Joseph A LopezBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Jane AndersenBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Fiona TeaBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Vera MerhebBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Kristy NguyenBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Fiona X Z LeeBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Marzena J Fabis-PedriniCentre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, The University of Western Australia, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia.
Alicia ZouBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Ali BucklandCentre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, The University of Western Australia, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia.
Anthony FokDepartment of Neurology, Monash Health, Clayton, Victoria, Australia.
Michael H BarnettBrain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0002-2156-8864
Stephen W ReddelBrain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0002-0169-3350
Romain MarignierService de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro Inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer and Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Lyon, France.
Aseel El HajjService de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro Inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer and Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Lyon, France.
Mastura MonifMultiple Sclerosis and Neuroimmunology Research Groups, Department of Neuroscience, Monash University, Clayton, Victoria, Australia.
Anneke van der WaltMultiple Sclerosis and Neuroimmunology Research Groups, Department of Neuroscience, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-4278-7003
Jeannette Lechner-ScottDepartment of Neurology, John Hunter Hospital, Newcastle, New South Wales, Australia.
Allan G KermodeCentre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, The University of Western Australia, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia.ORCID 0000-0002-4476-4016
Tomas KalincikClinical Outcomes Research Unit (CORe), Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-3778-1376
Simon A BroadleySchool of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.ORCID 0000-0002-9429-4307
Russell C DaleSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-2495-1826
Sudarshini RamanathanTranslational Neuroimmunology Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.ORCID 0000-0002-0294-9768
Fabienne BrilotBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia fabienne.brilot@sydney.edu.au.ORCID 0000-0002-7025-2276
on behalf the Australasian MOGAD Study Group
The University of Sydney · AUChildren's Hospital at Westmead · AUMonash University · AUMurdoch University · AUUniversité Claude Bernard Lyon 1 · FRGriffith University · AUJohn Hunter Hospital · AUMonash Health · AUThe Royal Melbourne Hospital · AUThe University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyelin oligodendrocyte glycoprotein (MOG) IgG seropositivity is a prerequisite for MOG antibody-associated disease (MOGAD) diagnosis. While a significant proportion of patients experience a relapsing disease, there is currently no biomarker predictive of disease course. We aim to determine whether MOG-IgG epitopes can predict a relapsing course in MOGAD patients.

methodsMOG-IgG-seropositive confirmed adult MOGAD patients were included (n=202). Serum MOG-IgG and epitope binding were determined by validated flow cytometry live cell-based assays. Associations between epitopes, disease course, clinical phenotype, Expanded Disability Status Scale and Visual Functional System Score at onset and last review were evaluated.

resultsOf 202 MOGAD patients, 150 (74%) patients had MOG-IgG that recognised the immunodominant proline42 (P42) epitope and 115 (57%) recognised histidine103/serine104 (H103/S104). Fifty-two (26%) patients had non-P42 MOG-IgG and showed an increased risk of a relapsing course (HR 1.7; 95% CI 1.15 to 2.60, p=0.009). Relapse-freedom was shorter in patients with non-P42 MOG-IgG (p=0.0079). Non-P42 MOG-IgG epitope status remained unchanged from onset throughout the disease course and was a strong predictor of a relapsing course in patients with unilateral optic neuritis (HR 2.7, 95% CI 1.06 to 6.98, p=0.038), with high specificity (95%, 95% CI 77% to 100%) and positive predictive value (85%, 95% CI 45% to 98%).

conclusionsNon-P42 MOG-IgG predicts a relapsing course in a significant subgroup of MOGAD patients. Patients with unilateral optic neuritis, the most frequent MOGAD phenotype, can reliably be tested at onset, regardless of age and sex. Early detection and specialised management in these patients could minimise disability and improve long-term outcomes.

Indexed as

AutoantibodiesImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinRecurrenceAdultBiomarkersEpitopesFemaleHumansMaleMiddle AgedOptic NeuritisAutoantibodiesBiomarkersEpitopesImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinIMMUNOLOGYMULTIPLE SCLEROSISNEUROIMMUNOLOGY

Identifiers

PMID38290838
PMCPMC11103329
OpenAlexW4391343462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.